Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY M KAPLAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1730176041
CMS profile
124198
Location
LENEXA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$232,340.24

564 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 12 of 12; records 551–564 of 564 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY M KAPLAN

NPI 1730176041 · CMS profile ID 124198

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

LENEXA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 12 of 12; records 551–564 of 564 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730176041?year=2019&recipient=provider&page=12#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY M KAPLAN, NPI 1730176041, CMS profile ID 124198. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–564 of 564 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730176041?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JEFFREY M KAPLAN, NPI 1730176041, CMS profile ID 124198. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–564 of 564 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730176041?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JEFFREY M KAPLAN, NPI 1730176041, CMS profile ID 124198, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 12; records 551–564 of 564 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1730176041?year=2019&recipient=provider&page=12#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

564 matching records · $232,340.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 564 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 551–564 of 564.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $12.0701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670632187 CMS
Biogen, Inc. $15.8101/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660627449 CMS
Lilly USA, LLC $227.9201/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870859 CMS
Lilly USA, LLC $97.4701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657881243 CMS
Teva Pharmaceuticals USA, Inc. $7.1301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697677801 CMS
Lilly USA, LLC $1,400.0001/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657870863 CMS
Lilly USA, LLC $700.0001/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657884643 CMS
Biogen, Inc. $9.4901/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660627441 CMS
Amgen Inc. $2,400.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662485159 CMS
Amgen Inc. $2,400.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662485169 CMS
Amgen Inc. $2,400.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662485181 CMS
Amgen Inc. $400.0001/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662485185 CMS
Amgen Inc. $15.0001/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662485189 CMS
Lilly USA, LLC $10.7401/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657894883 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $232,340.24 564
PY2020 $234,765.95 343
PY2021 $300,772.21 322
PY2022 $375,862.01 424
PY2023 $285,204.19 331
PY2024 $282,847.23 310
PY2025 $213,232.70 299

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $171,207.78 60
PY2024 Principal investigator $430,282.35 98
PY2023 Recipient $4,164.32 5
PY2023 Principal investigator $395,223.23 118
PY2022 Recipient $5,618.00 2
PY2022 Principal investigator $604,795.96 54
PY2021 Recipient $23,294.33 2
PY2021 Principal investigator $275,148.95 105
PY2020 Principal investigator $338,046.58 80
PY2019 Recipient $2,000.00 2
PY2019 Principal investigator $252,124.24 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $240.00 12/31/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE SPECIALTY CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202534281
Principal investigator 1 ABBVIE INC. $100.00 12/31/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE SPECIALTY CENTER
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202534283
Principal investigator 1 ABBVIE INC. $100.00 12/31/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE SPECIALTY CENTER
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202534285
Principal investigator 1 TG Therapeutics, Inc. $11,000.00 12/09/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE CENTER PHYSICIANS GROUP
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200767
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,942.32 09/09/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301609
Principal investigator 1 TG Therapeutics, Inc. $31,400.00 08/31/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE CENTER PHYSICIANS GROUP
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200735
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636107
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636109
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636113
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636116
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636120
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636124
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636129
Principal investigator 1 Roche Products Limited $254.00 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636136
Principal investigator 1 Roche Products Limited $76.20 06/25/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636140
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 06/05/2025 Non-covered Recipient Entity
KC RESEARCH CENTER
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200367
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118036
Principal investigator 1 EMD Serono, Inc. $345.00 05/05/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118032
Principal investigator 1 PFIZER INC. $2,325.60 04/24/2025 Non-covered Recipient Entity
Overland Park Surgical Specialties LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228722998
Principal investigator 1 ABBVIE INC. $600.00 04/03/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202469429
Principal investigator 1 ABBVIE INC. $600.00 04/03/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202469432
Principal investigator 1 GENZYME CORPORATION $6,053.00 04/02/2025 Non-covered Recipient Entity
Overland Park Surgical Specialties LLC College Park Family Care Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138975
Principal investigator 1 EMD Serono, Inc. $440.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118040
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118045
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636002
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636006
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636008
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636013
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636017
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636021
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636026
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636032
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636036
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636039
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636042
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636046
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636050
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636055
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636059
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636063
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636067
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636071
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636078
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636082
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636085
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636090
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636096
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636100
Principal investigator 1 Roche Products Limited $254.00 03/24/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211636104
Principal investigator 1 Eli Lilly and Company $105.40 03/10/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187888304
Principal investigator 1 ABBVIE INC. $1,567.00 03/06/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC DBA COLLEGE PARK FAMILY CARE CENTER PHYSICIANS GROUP
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202456276
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,245.00 02/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190299615
Principal investigator 1 EMD Serono, Inc. $233.00 02/20/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118451
Principal investigator 1 EMD Serono, Inc. $233.00 02/20/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118453
Principal investigator 1 EMD Serono, Inc. $233.00 02/20/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118455
Principal investigator 1 Eli Lilly and Company $1,845.00 02/18/2025 Non-covered Recipient Entity
OVERLAND PARK SURGICAL SPECIALTIES
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187889736
Principal investigator 1 GENZYME CORPORATION $11,892.35 02/10/2025 Non-covered Recipient Entity
Overland Park Surgical Specialties LLC College Park Family Care Center
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138931
Principal investigator 1 Novartis Pharmaceuticals Corporation $34.20 01/31/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE CENTER
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190302039
Principal investigator 1 Novartis Pharmaceuticals Corporation $51,967.32 01/31/2025 Non-covered Recipient Entity
ADVENT NEUROLOGY CLINIC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190305039
Principal investigator 1 Novartis Pharmaceuticals Corporation $221.65 01/01/2025 Non-covered Recipient Entity
COLLEGE PARK FAMILY CARE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301607